ESR1 and breast carcinoma: Finally, we explored the combination of the survivin dominant-negative mutant with either Taxol or a gamma secretase inhibitor, as Notch signaling has been reported to increase survivin levels in basal-like breast cancer but not in ER+ breast cancer [36,37].